Document 3245 DOCN M94A3245 TI Identification of a complement activating site in gp120. DT 9412 AU Susal C; Kirschfink M; Kropelin M; Daniel V; Opelz G; Institute of Immunology, University of Heidelberg, Germany. SO Int Conf AIDS. 1994 Aug 7-12;10(1):12 (abstract no. 023A). Unique Identifier : AIDSLINE ICA10/94369330 AB OBJECTIVE: We showed recently that rgp120 of HIV-1, either attached to microtiter plates or bound to normal CD4+ cells, activates the human complement system in the absence of anti-gp120 antibodies. This may represent a mechanism for the elimination of uninfected CD4+ cells by the reticuloendothelial system and play a role in the enhancement of infection by HIV-1. In the current study we attempted to identify complement activation sites in gp120. METHODS: Equal amounts of 21 different gp120-peptides were attached to microtiter plates. After incubation with normal, anti-gp120 neg. human serum (n = 10) deposition of complement proteins was assessed by ELISA. RESULTS: Complement proteins C4, C3d, C5b-9 and properdin were found to bind to a peptide covering positions 228-246 when incubated with any normal human serum. Complement activation by the peptide was as strong as by aggregated IgG, by complete rgp120, as well as by the previously described complement activating gp41-peptide 609-623. Activation of complement occurred primarily via the classical pathway and was abrogated in the presence of EDTA, Mg/EGTA or C4-deficient human serum. Peptides partly overlapping the sequence 228-246 activated complement to a lesser extent. CONCLUSIONS: Our data indicate that a specific site in gp120 is able to activate complement in normal human serum via the classical pathway in the absence of anti-gp120 and independent of glycosylation. DE Complement/ISOLATION & PURIF *Complement Activation Complement Pathway, Classical Enzyme-Linked Immunosorbent Assay Human HIV Envelope Protein gp120/*IMMUNOLOGY HIV Envelope Protein gp41/IMMUNOLOGY HIV-1/*IMMUNOLOGY MEETING ABSTRACT SOURCE: National Library of Medicine. NOTICE: This material may be protected by Copyright Law (Title 17, U.S.Code).